SeouLinBioscience (038070) Financial Statements

OverviewFinancialsChecksFilings

In fiscal year 2025, SeouLinBioscience (038070) reported revenue of 77.1 billion KRW.

Income Statement

YearRevenueOp ProfitNet IncomeSource
202577.1 billion KRW692 million KRW574 million KRW[source]
202475.4 billion KRW953 million KRW3.1 billion KRW[source]
202389.6 billion KRW2.5 billion KRW-2.3 billion KRW[source]
2022102.4 billion KRW8.6 billion KRW10.0 billion KRW[source]
202180.7 billion KRW7.3 billion KRW15.8 billion KRW[source]

Balance Sheet

YearTotal AssetsTotal LiabilitiesTotal EquitySource
2025115.5 billion KRW31.7 billion KRW83.8 billion KRW[source]
202498.4 billion KRW13.9 billion KRW84.6 billion KRW[source]
2023111.7 billion KRW27.3 billion KRW84.4 billion KRW[source]
2022128.2 billion KRW45.8 billion KRW82.3 billion KRW[source]
2021133.1 billion KRW59.4 billion KRW73.8 billion KRW[source]

Cash Flow

YearOperatingInvestingFinancingSource
20254.8 billion KRW-16.8 billion KRW13.6 billion KRW[source]
2024-4.6 billion KRW6.4 billion KRW-7.5 billion KRW[source]
2023931 million KRW27.5 billion KRW-22.8 billion KRW[source]
2022-4.4 billion KRW-2.7 billion KRW1.1 billion KRW[source]
20218.9 billion KRW-31.5 billion KRW29.0 billion KRW[source]
Financials & Filings: DART (traceable by receipt number) · Prices: Financial Services Commission · Data Sources · Last checked: 2026-08-29 · About · Delisting market cap threshold: KOSPI 5B KRW / KOSDAQ 4B KRW (per listing rules) · This page provides factual information, not investment advice